• In May 2024, Merck closed a deal to acquire EyeBio for up to 3 billion, gaining Restoret—its midstage wet AMD/diabetic macular edema drug—strengthening its position in ophthalmology and addressing portfolio diversification post‑Keytruda era.

• In May 2025, the European Medicines Agency endorsed a six‑month dosing interval for high‑dose Eylea HD (8 mg), offering wet AMD and diabetic macular edema patients longer-lasting treatment and a competitive edge over Roche’s Vabysmo.

In this report, the Age-Related Macular Degeneration Therapeutics Market has been segmented by Drug Type, Disease Indication, Distribution Channel, and Geography.

Age-Related Macular Degeneration Therapeutics Market, Segmentation by Drug Type

The Age-Related Macular Degeneration Therapeutics Market has been segmented by Drug Type into Ranibizumab, Aflibercept, Bevacizumab, Pegaptanib, Brolucizumab, and Others.

Ranibizumab

Ranibizumab is a widely used anti-VEGF agent approved for treating wet age-related macular degeneration. Known for its strong clinical efficacy and safety profile, it remains a preferred choice in many countries. This drug accounts for 34% of the market share.

Aflibercept

Aflibercept is a leading biologic therapy offering extended dosing intervals and high efficacy in managing neovascular AMD. It is often selected for patients needing less frequent injections. This segment represents 28% of the market share.

Bevacizumab

Bevacizumab, though used off-label, is a cost-effective anti-VEGF therapy for AMD. It is especially common in regions with budget constraints and continues to see wide clinical use. This segment holds 19% of the market share.

Pegaptanib

Pegaptanib was among the first anti-VEGF agents introduced for AMD. While largely replaced by newer drugs, it still sees selective use in early-stage treatment. This drug accounts for 7% of the market share.

Brolucizumab

Brolucizumab is a next-generation therapy designed to improve durability and visual outcomes with less frequent dosing. It is gaining traction in patients with inadequate response to prior therapies. This segment represents 8% of the market share.

Others

This segment includes emerging therapies and alternative treatments such as gene therapies, combination agents, and novel VEGF inhibitors under development or in limited use. It holds 4% of the market share.

Age-Related Macular Degeneration Therapeutics Market, Segmentation by Disease Indication

The Age-Related Macular Degeneration Therapeutics Market has been segmented by Disease Indication into Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.

Dry Age-Related Macular Degeneration

Dry AMD is the more common form, characterized by gradual vision loss due to drusen buildup and retinal thinning. Although fewer treatment options exist compared to wet AMD, emerging therapies are under development to address this unmet need. This segment accounts for 38% of the market share.

Wet Age-Related Macular Degeneration

Wet AMD involves abnormal blood vessel growth and leakage beneath the retina, leading to rapid vision loss. It is the primary focus of current biologic treatments, including anti-VEGF therapies. This segment dominates the market with 62% of the share.

Age-Related Macular Degeneration Therapeutics Market, Segmentation by Distribution Channel

The Age-Related Macular Degeneration Therapeutics Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital Pharmacies

Hospital pharmacies play a key role in dispensing specialized AMD therapeutics, particularly for patients undergoing in-clinic injections and follow-up care. These settings offer close coordination between ophthalmologists and pharmacists. This channel holds 47% of the market share.

Retail Pharmacies

Retail pharmacies provide easier access to prescribed oral or supportive AMD medications. They serve patients in both urban and suburban areas and are critical in outpatient treatment continuity. This segment accounts for 35% of the market share.

Online Pharmacies

Online pharmacies are gaining traction due to convenience, cost savings, and growing acceptance of digital healthcare solutions. They are especially favored by elderly patients for home delivery of ongoing therapies. This segment represents 18% of the market share.

Age-Related Macular Degeneration Therapeutics Market, Segmentation by Geography

In this report, the Age-Related Macular Degeneration Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Age-Related Macular Degeneration Therapeutics Market Share (%) by Geographical Region

North America

North America leads the AMD therapeutics market due to the high prevalence of age-related vision disorders, strong presence of leading biopharmaceutical companies, and advanced healthcare infrastructure. The United States and Canada are the primary contributors. This region holds 41% of the market share.

Europe

Europe maintains strong market performance, driven by widespread use of anti-VEGF therapies and increasing elderly population. Countries such as Germany, France, and the United Kingdom play significant roles. This region accounts for 30% of the market share.

Asia Pacific

Asia Pacific is witnessing rapid growth owing to rising awareness of early eye disease detection and improvements in ophthalmic care infrastructure. Major markets include China, Japan, and India. This region represents 20% of the market share.

Middle East and Africa

The Middle East and Africa region is experiencing gradual growth in AMD treatment access through expanding specialist eye care services and government health initiatives. Key countries include Saudi Arabia, UAE, and South Africa. This region contributes 5% of the market share.

Latin America

Latin America’s market is growing steadily, supported by improved access to ophthalmologic diagnostics and increasing focus on elderly care. Major contributors include Brazil, Mexico, and Argentina. This region holds 4% of the market share.

This report provides an in depth analysis of various factors that impact the dynamics of Age-Related Macular Degeneration Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Rising prevalence of AMD cases
• Growing geriatric population with vision disorders
• Advancements in biologic drug development

• Increasing demand for personalized AMD therapies - Playing a pivotal role in shaping the future of the AMD therapeutics market. As patient demographics become more diverse and complex, there is growing recognition that one-size-fits-all treatment models often fall short of delivering optimal outcomes. This has sparked considerable investment in developing tailor-made therapeutic solutions that align with each patient's genetic profile, disease stage, and lifestyle. Personalized medicine not only improves the efficacy of treatment but also reduces the risks of adverse drug reactions.

  Advances in genomics, molecular diagnostics, and data analytics are key enablers of this transformation. They allow for precise targeting of disease mechanisms specific to individual patients. Moreover, the development of biologics and biosimilars tailored to patients' needs has further supported the movement toward more personalized approaches. Pharmaceutical companies are increasingly leveraging biomarker-based research to stratify patients for clinical trials, thus enhancing the success rate of novel therapies.

  Personalized medicine also opens doors for companion diagnostics, which can identify suitable candidates for specific drugs. This not only ensures the right treatment reaches the right patient but also improves cost-effectiveness by eliminating ineffective interventions. These innovations are further backed by government and private funding, especially in regions like North America and Europe, where healthcare systems are actively embracing precision medicine models.

  As the market evolves, integrating AI-driven analytics and real-world evidence will continue to push personalized therapies to the forefront. Stakeholders across the value chain—from biotech firms to clinical researchers—are expected to prioritize the development of individualized AMD treatment regimens, helping to meet the rising expectations of both healthcare providers and patients alike.

Restraints:

• High cost of AMD treatment options
• Limited patient awareness in rural regions
• Side effects associated with long-term therapies

• Delays in drug approvals and regulations - A significant challenge in the AMD therapeutics market. The regulatory landscape for ophthalmic drugs is complex and time-consuming, often involving lengthy clinical trials, safety assessments, and compliance checks. These processes slow the pace at which new and innovative therapies reach the market, especially in cases involving biologics or gene therapies, which require specialized scrutiny by authorities such as the FDA and EMA.

  The necessity to adhere to strict regulatory standards also increases the overall cost and time required for drug development. Small and mid-sized pharmaceutical firms, in particular, may struggle to meet these demands, leading to a narrowed competitive landscape and fewer treatment options for patients. Furthermore, delays in approvals discourage investment in high-risk, high-reward therapies, hampering progress in more advanced treatment modalities.

  Regulatory uncertainty, especially across emerging economies, further restricts market access. Differences in approval timelines, documentation requirements, and pricing regulations between countries make global launch strategies more complex. Delayed reimbursement decisions and post-marketing surveillance requirements also discourage pharmaceutical companies from pursuing broader distribution.

  In the long run, these obstacles not only impede patient access to innovative care but also reduce industry profitability. Overcoming this restraint will require streamlined regulatory harmonization, improved collaboration between regulators and drug developers, and increased investment in regulatory technology (RegTech) to enhance efficiency and reduce turnaround times.

Opportunities:

• Emerging pipeline of gene therapy solutions
• Expansion into untapped emerging markets
• Collaborations for novel drug innovations

• Integration of AI in AMD diagnostics - As a transformative opportunity in the market. By utilizing artificial intelligence and machine learning algorithms, healthcare providers can now detect early-stage macular degeneration with remarkable precision. AI-driven diagnostic tools have the ability to analyze retinal scans, OCT images, and fundus photography faster and more accurately than traditional methods, reducing diagnosis time and improving clinical decision-making.

  One of the key advantages of AI is its potential for predictive analytics. It enables the identification of at-risk individuals before symptoms manifest, allowing for preventive treatment planning and better management of disease progression. Companies are investing in AI-powered diagnostic platforms that combine data from multiple imaging modalities, enhancing the overall effectiveness of screening programs. These systems are particularly useful in underserved or rural areas where access to skilled ophthalmologists is limited.

  AI integration also facilitates remote monitoring and teleophthalmology, a critical feature in a post-pandemic healthcare environment. By automating diagnostic workflows, healthcare systems can better manage patient loads and deliver personalized follow-up care. Additionally, AI contributes to the creation of standardized and objective diagnostic criteria, minimizing inter-observer variability and improving clinical outcomes.

  As the demand for cost-efficient and scalable diagnostics increases, the incorporation of AI technologies into AMD therapeutic strategies is expected to gain traction. Collaborations between tech companies and healthcare providers will further accelerate innovation, making AI-enabled diagnostic tools a cornerstone of future AMD management and treatment planning.